Science more challenging than entrepreneurship, says Krishna Ella

Bharat Biotech may have gained immense popularity with its COVID-19 vaccine Covaxin, but the firm's founder and chairman Krishna Ella says science remains his passion

Krishna Ella, chairman & MD,  Bharat Biotech
Krishna Ella, chairman & MD, Bharat Biotech
Press Trust of India Hyderabad
2 min read Last Updated : Mar 22 2022 | 11:44 PM IST

Bharat Biotech may have gained immense popularity with its COVID-19 vaccine Covaxin, but the firm's founder and chairman Krishna Ella says science remains his passion and that being a vaccine maker is more challenging than entrepreneurship.

His company's website states that Krishna Ella is a research scientist in molecular biology.

"I am still a scientist... Science is my passion," Ella said when asked which is more exciting and challenging to him between being a scientist or entrepreneur.

He was speaking during a conversation with Uma Chigurupati, Chairperson of FICCI Ladies Organisation (FLO), Hyderabad on Tuesday. Suchitra Ella, JMD of Bharat Biotech, also participated in the interactive session.

Science is also very challenging as scientists working in the vaccine field need to compete globally, Krishna Ella said.

Systems, once they are put in place, can drive entrepreneurship, but science cannot be driven by entrepreneurship, he added.

Safety was at the top of the mind while setting out on the journey of making vaccines, he said.

"I looked at only one thing. Safety, safety, safety. It is the most crucial thing in a vaccine," he said, adding that even if a vaccine does not end up helping a person, it should not harm the recipient.

Telangana Governor Tamilisai Soundararajan, who was the chief guest at the event, praised the efforts of Krishna Ella and Suchitra Ella in bringing out Covaxin during the pandemic.

Soundararajan, who felicitated Krishna Ella and Suchitra Ella on the occasion, said the country is proud of the indigenous vaccine and the vaccine makers.

The country has successfully taken up the world's largest vaccination drive to combat COVID-19, she said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Bharat BiotechEntrepreneurshipCoronavirus Vaccine

First Published: Mar 22 2022 | 11:44 PM IST

Next Story